1067718-07-3

Basic information

• Product Name: TERT-BUTYL 4-(3-NITROPYRIDIN-4-YLAMINO)PIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-(3-NITROPYRIDIN-4-YLAMINO)PIPERIDINE-1-CARBOXYLATE;1-PIPERIDINECARBOXYLIC ACID, 4-[(3-NITRO-4-PYRIDINYL)AMINO]-, 1,1-DIMETHYLETHYL ESTER
• CAS NO: 1067718-07-3
• Molecular Formula: C₁₅H₂₂N₄O₄
• Molecular Weight: 322.35958
• Mol File: 1067718-07-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 4-(3-NITROPYRIDIN-4-YLAMINO)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(3-NITROPYRIDIN-4-YLAMINO)PIPERIDINE-1-CARBOXYLATE(1067718-07-3)
• EPA Substance Registry System: TERT-BUTYL 4-(3-NITROPYRIDIN-4-YLAMINO)PIPERIDINE-1-CARBOXYLATE(1067718-07-3)

Safety Data

• Hazardous Substances Data: 1067718-07-3(Hazardous Substances Data)

Upstream product

• 5435-54-1 4-hydroxy-3-nitropyridine 

Downstream Products

• 185962-07-6 1-(piperidin-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one 

Relevant articles and documents

Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists

Replacement of the polar head of our previous series of 1-acyl-4-[(2-methyl-3-pyridyl)-cyanomethyl]piperazines with a 2-methylimidazo[4,5-c]pyridine group has led to the identification of a new series of 1-[(1-acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor (PAF) antagonists. On the basis of the general structure - activity relationship trends found for the acyl substituent in our earlier series, five groups of compounds were tested, diaryl- or alkylarylpropanoyl derivatives, their 3-hydroxy-substituted analogues, and urea, carbamate and amino acid derivatives. The optimal compound 19 (UR-12670), bearing the 3,3-diphenylpropanoyl moiety, exhibited very high in vitro and in vivo potency (IC50 = 0.0076 μM for the in vitro PAF-induced platelet aggregation assay, ID50 = 0.0086 mg/kg for the in vivo PAF-induced hypotension test in normotensive rats, and ID50 = 0.092 mg/kg po and 0.0008 mg/kg iv for the PAF-induced mortality test in mice). Compound 19 also showed long duration of activity. It gave 100% protection against PAF-induced mortality in mice 7 h after iv administration of a single dose of 1 mg/kg and also provided 100% inhibition of PAF-induced aggregation in dog whole blood 6 h after iv administration of the same dose. The lead structure 19 has been selected for in-depth pharmacological evaluation.